A Clinical Trial to Look at the Safety and Immune Responses of the RNA‑based Vaccine BNT168 in Adults Living With or Without HIV

Trial status:Will Be Recruiting

Trial ID:

BNT168-01

NCT ID:

NCT07698600

EudraCT ID:

N/A

EU Trial (CTIS) Number:

N/A

Collaborator:

N/A

Will Be Recruiting

Trial Details

This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and how it affects the amount of virus in the body.

Medical Condition

Unmapped

Study Drug

BNT168

Phase

Phase 1

Type

Interventional

Estimated Enrolment

126

Estimated Trial Date

Jul 2026 - Jan 2028

Trial Participant Requirements

Age

18 - 50 Years

Sex

Female & Male

Healthy Volunteers

Yes

Inclusion and Exclusion Criteria

Inclusion criteria

Are 18 to 50 years of age inclusive at the time of giving informed consent.
For PLWOH: Individuals who are HIV-1 and HIV-2 negative at Visit 0. For PLWH: Individuals who are HIV-1 positive and HIV-2 negative at Visit 0.
Have not received an HIV vaccination or HIV broadly neutralizing antibody in another clinical study.
Are overall healthy as defined in the protocol.
Individuals who have screening hematology and/or blood chemistry laboratory values as defined in the protocol.
For PLWOH, starting at Visit 0 and continuously until the last planned visit in this study, individuals who:
- Are assessed by the investigator as having a low likelihood of acquiring HIV and are committed to avoiding behaviors associated with a higher likelihood of acquiring HIV until the End of Study Visit.
- Agree to discuss HIV disease risks.
- Agree to HIV infection risk reduction counseling.
For PLWH, individuals who:
- Have been on stable continuous cART for at least 12 months (defined as no interruptions longer than 14 continuous days) and with no changes in the components of the cART for at least 12 weeks prior to Visit 1.
- Are not on a non-nucleoside reverse transcriptase inhibitor at screening.
- Have never received lenacapavir and have not received other long-acting antiretroviral therapies in the last 2 years (i.e., intramuscular cabotegravir, cabotegravir-rilpivirine).
- Are willing to undergo HIV transmission risk reduction counseling and to maintain low-risk behavior to protect their partners.
- Have a CD4+ T cell count of ≥500 cells/µL at Visit 0.
- Per medical history, any available prior CD4+ T cell count must be ≥350 cells/µL.
- Have plasma HIV-1 RNA levels of \<50 cps/mL for ≥6 months prior to study entry per investigator review of records and/or participant history (single measurements of \<200 cps/mL are allowed if preceded and followed by values of \<50 cps/mL).
- Are willing to stop cART and undergo ATI at the timepoint defined in the protocol.
- Are willing to re-initiate cART upon meeting cART restart criteria.
- Site investigator anticipates that a fully active alternative cART regimen could be constructed and would be available in the event of virologic failure on the participant's current cART regimen.
Agree not to donate blood from the time of first IMP administration until 90 days after the last IMP administration for PLWOH and until the End of Study Visit for PLWH.

Exclusion criteria

Have had major surgery (e.g., major cardiopulmonary or abdominal operations) as per the investigator's judgment within 4 weeks before Visit 0, or will not have fully recovered from surgery, or have major surgery planned during the time the participants are expected to participate in the study.
Have an abnormal electrocardiogram at Visit 0 as specified in the protocol.
Have any existing condition which may affect IMP injection and/or assessment of local reactions, e.g., tattoos, severe scars, etc.
Have any bleeding diathesis or condition associated with prolonged bleeding that, in the opinion of the investigator, could compromise their wellbeing if they participate in the study.
Have any current febrile illness (body temperature \>38.0°C/\>100.4°F) or other acute illness within 48 hours prior to IMP administration
Have any current or history of cardiovascular diseases, e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias, or any clinically significant cardiac disease per the investigator's judgment.
Have Grade ≥2 hypertension per Food and Drug Administration toxicity grading scale at screening.
Have a known or suspected impairment/alteration of immune function, autoimmune disease, or immunodeficiency (except HIV for PLWH), including receipt of any immunostimulant, immunomodulator, immunosuppressive medication, immunoglobulin, or blood/plasma product within 60 days prior to Visit 1 or planned administration during the study. Use of inhaled, intranasal, topical, or locally injected corticosteroids (e.g., intraarticular or intrabursal administration) is acceptable.
Have a history of malignancy within 5 years before screening. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is considered in the investigator's judgment to have minimal risk of recurrence. Any malignancy that is an AIDS-defining illness per protocol is exclusionary regardless of perceived risk of recurrence.
Have received any live vaccines within 28 days prior to Visit 0 or any other vaccines within 14 days prior to Visit 0 or who are planning to receive any vaccine within 28 days of each IMP dose. When possible, standard of care vaccinations should be planned with the study interventions in mind.
For PLWH: Have a history of opportunistic infections and/or AIDS-defining illnesses according to the US Centers for Disease Control and Prevention 2014 and the National Institutes of Health 2024.
For PLWOH: Have current untreated or incompletely treated active tuberculosis infection (by history or concerning symptoms). For PLWH: Have current untreated or incompletely treated active tuberculosis infection (by history or concerning symptoms or sputum molecular testing) or current latent tuberculosis infection (by blood interferon-gamma release assay [IGRA]). Not excluded: Participants who have a positive IGRA but were fully treated for latent or active tuberculosis infection, per history, review of available records, and per investigator discretion.
For PLWH: Have untreated or incompletely treated syphilis or genital, oropharyngeal or rectal gonorrhea or chlamydia infection.
For PLWH: Have a history of multi-class drug resistant HIV-1 infection defined as resistance to three or more classes of HIV drugs.
Have an estimated glomerular filtration rate of \<45 mL/min/1.73 m2 using the 2021 chronic kidney disease epidemiology creatinine equation.
History of any serious adverse reactions (including anaphylaxis, respiratory distress, angioedema, or urticaria) to vaccines or to vaccine components such as lipids.
Have a history of progressive or severe neurologic disorder, seizure disorder, or Guillain-Barré syndrome.
Have a history of diabetes mellitus type 1 or type 2, a screening hemoglobin A1c ≥6.5%, or are taking any medication for treatment of diabetes. (Not excluded: A history of isolated gestational diabetes.)

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Trial Locations

No locations found.